

# 14<sup>th</sup> NATIONAL PHARMACEUTICAL CONGRESS

[www.pharmacongress.info](http://www.pharmacongress.info)



## INTRODUCING YOUR 2020 Faculty

### **STEPHANIE BABBITT**

*Senior Director, Services. McKesson Specialty Health*

Stephanie Babbitt holds a B.Sc.N. degree from Laurentian University School of Nursing, Healthcare Leadership Develop Program from the DeGroot School of Business, and a D.O.M.P. from the Canadian College of Osteopathy. Leveraging her strong background in healthcare, she has held progressive roles within Specialty Programs over the past 11 years. As the Senior Director, Patient Services at McKesson Specialty Health she is responsible for leading the Specialty Programs business unit, leading strategic initiatives that support patients, providers, and manufacturers by creating unified solutions to meet the needs of all stakeholders.

---

### **BRIAN BLOOM**

*Founder, Bloom Burton & Co.*

Brian Bloom is a co-founder of Bloom Burton & Co. and serves as the firm's Chairman and Chief Executive Officer. Before co-founding Bloom Burton in 2008, Brian spent six years at Dundee Securities in the healthcare and biotechnology institutional sales and equity research groups. Brian received an Honours Bachelor of Science in Biochemistry from McMaster University and subsequently studied at the Mount Sinai Graduate School for Biological Sciences of New York University, with a focus in molecular endocrinology and biophysics.

---

### **PETER BRENDERS**

*CEO of the New Brunswick Health Research Foundation*

Peter Brenders currently the CEO of the New Brunswick Health Research Foundation and Managing Director of the specialist management services company TO4 Group Inc. Peter was also the Founder, President and CEO of Kontollo Health Inc., a US-based telehealth company, founding CEO of Inagene Diagnostics and was the General Manager at Sanofi Genzyme for over 7 years. Peter led BIOTECanada for almost 8 years and has worked in executive roles at Genzyme and Schering-Plough Canada. Peter

also serves on the clinical research unit advisory board of the Montreal Neurological Institute, the advisory boards of mitoNET, and the Professional Advisory Council for the MMASc of Western University. He was recently on the board of VIDO-InterVac and was its Chair of the Finance and Audit Committee. Peter was inducted into the Canadian Healthcare Marketing Hall of Fame in 2016

---

### **BRIAN CANESTRARO**

#### ***General Manager, Intercept Pharma Canada***

Brian is the General Manager for Intercept Pharma Canada, responsible for the leadership of Intercept's Canadian Operations.

Brian has over 20 years' experience in the innovative pharmaceutical industry where he has held senior roles across Sales & Marketing, Market Access and General Management. Brian has successfully led the launches of multiple specialty brands, corporate functions, business units and most recently, a biopharma company in the Canadian marketplace. Brian is passionate about the innovative pharmaceutical industry and motivated by the opportunity to advance healthcare opportunities for Canadians.

Brian holds an honours degree in Kinesiology from the University of Western Ontario and an MBA from the University of Leicester.

---

### **ANDREW CASEY**

#### ***President and CEO, BIOTECCanada***

Andrew Casey became president and CEO of BIOTECCanada in August, 2012. In this role, Andrew is responsible for the strategic operations of the Association representing Canada's biotechnology sector. He is the lead spokesperson for Canada's biotechnology industry communicating on the industry's behalf with government, regulators, international bodies, media and the Canadian public.

In his capacity as head of BIOTECCanada, Andrew also serves as Director, Board of Directors, BIOTECCanada; Vice Chair, International Council of Biotechnology Associations (ICBA); Director, Board of Directors, Institute for Research in Immunology and Cancer, Commercialization of Research (IRICoR); and Director, Board of Directors, Arthritis Alliance of Canada (AAC).

Prior to joining BIOTECCanada, Andrew served from 2004-2012 as Vice President, Public Affairs and International Trade with the Forest Products Association of Canada (FPAC). From 1993-2004 he was Assistant Vice-President, Government Relations with the Canadian Life and Health Insurance Association. Between 1989 and 1993, Andrew worked on Parliament Hill as a political advisor in the office of the Federal Ministry of Finance. Andrew is a native of Montreal. After attending Loyola High School (Montreal) and St. Lawrence CEGEP (Quebec City) he graduated from Carleton University (Ottawa) with a degree in Political Science.

---

### **JAMES CRAN**

#### ***President, Pharma Consultants Inc.***

---

**TIANA DIMICHELE**

*Director, Business Development, Impres Inc.*

Tiana DiMichele is the Director of Business Development for Impres, Canada's 'Next Generation' Commercial Partner. She offers a unique perspective, having worked on both the corporate and service partner sides of the industry during her 15 years in pharmaceuticals and biotech.

Tiana began her career in healthcare communications before branching out to co-found a public relations agency with clients ranging from start-up to big pharma. Following that she held progressive positions in sales and marketing at Bayer Canada, and subsequently led all commercial and corporate affairs functions at Acerus, a Canadian-based, publicly traded specialty pharma company. Her passion is for building impactful company and brand strategies that translate into successful teams, and with that comes a focus on driving key results, adapting to new insights, and leading through challenge and change.

Tiana holds an Honours Bachelor of Science degree in Biology and Psychology from the University of Toronto, a post-graduate Corporate Communications Certification from York University, and a Strategic Brand Management Certification from the Schulich School of Business. She has served as a moderator and speaker for a number of industry conferences, podcasts and events.

---

**JOEL ERICKSON**

*Executive Vice-President, Ashfield Healthcare Canada*

Joel Erickson is the Executive Vice-President of the Canadian division of Ashfield Healthcare, a prominent global contract services organization. Joel has over 20 years of experience in the industry holding roles in healthcare communications, marketing and sales working with Canada's leading Pharmaceutical, Medtech, Biotech and OTC healthcare companies designing, developing and deploying fit-for- purpose go to market strategies.

At Ashfield Healthcare Canada Joel oversees the Business Development and Partnerships of more than 60 accounts leveraging Ashfield's Field, Contact Center, Patient Engagement and Fulfillment Solutions to drive greater flexibility, efficiency and ultimately outcomes for their clients.

Joel holds a degree from Concordia University in Montreal, and was a member of the Board of Directors of the Pharmaceutical Marketing Club of Quebec (PMCQ) for many years including President during the 2005-2006 season.

---

**JASON FIELD, PhD**

*President and CEO, Life Sciences Ontario*

Dr. Jason Field is President and CEO of Life Sciences Ontario (LSO). LSO collaborates with governments, academia, industry and other life science organizations across Canada to promote and encourage commercial success throughout the diverse sector. Jason obtained his PhD in Chemistry from the University of Massachusetts and his B.Sc from the University of Waterloo. Jason's professional experience includes the pharmaceutical industry and the Ontario government before joining LSO as Executive Director in October, 2011. He was appointed as President and CEO in April, 2014. He serves on several boards and advisory committees including UofT's Translational Research Program, ReMAP, BioTalent Canada and Research Canada. Jason is the 2017 recipient of the Distinguished Alumni Award from the University of Waterloo.

---

## **PAT FORSYTHE**

***General Manager, Eisai Inc.***

Eisai is a Specialty Pharma company focused on Neurology and Oncology. The company is focused on improving patients' lives in Epilepsy, and Breast, Thyroid, Kidney and Liver cancer. Additionally, Eisai is focused on Epilepsy and seizure disorders. A primary research focus is Dementia, as Eisai hopes to address the needs of those suffering from this devastating disease.

Pat has over 25 years of commercial experience in the Canadian pharmaceutical industry in a range of therapeutic areas from Oncology to Specialty Biotech to traditional Primary Care. He has been involved in over 15 unique launches in a variety of therapeutic areas.

Attention to the needs of patients and the community are central priorities that have shaped the direction and activities of the companies he has led. This approach has helped create a team and company culture that is characterized by its commitment to excellence; strong collaboration across disciplines and the ability support the patients and customers they serve.

---

## **PAMELA FRALICK**

***President, Innovative Medicines Canada***

Driven by a life-long commitment to improving Canadians' health and well-being, Pamela works with Canada's research-based pharmaceutical companies to ensure that Canadians continue to have timely access to the medicines they need.

Prior to joining Innovative Medicines Canada, Pamela was President and CEO of the Canadian Cancer Society, Canada's largest health charity. Pamela previously served as President and CEO of the Canadian Healthcare Association (now Healthcare CAN), the Canadian Physiotherapy Association, the Collegium of Work and Learning and the Canadian Centre on Substance Abuse. Pamela has also held senior public service positions with Health Canada and the Department of National Defense. She has also been active in many organizations as a senior volunteer, including the Centre for Addiction and Mental Health (Chair), the University of Ottawa Institute of Mental Health Research, Outward Bound Canada (Chair), the Canada Dance Festival (Chair), Triathlon Canada and the International Triathlon Union. She currently serves on the Board of Outward Bound International and the Global Advisory Council of the

**KARL FRANK, BSc. (Pharm)**

***Divisional Director, Bayshore Specialty Rx***

Karl Frank is passionate about supporting patient care and the need to streamline the delivery of healthcare in the community. He has spearheaded the growth of Bayshore Specialty Rx into one of Canada's leading service providers of specialty healthcare.

His vision and leadership spans across the entire operation of the Bayshore Specialty Healthcare division which encompasses patient assistance programs, call centre services, wholesale and 3PL, pharmacy, infusion clinic networks and nursing services. In addition to his leadership on Patient Assistance Programs, he is responsible for the LHIN Home Infusion business unit and Diabetes Express.

Prior to joining Bayshore, Karl served as Vice President of Pharmacy Merchandising and Operations at Loblaw Companies Ltd., where he provided leadership during a time of significant change in the Canadian pharmaceutical industry. He is a graduate of the University of Alberta Pharmacy program and is a licensed pharmacist in British Columbia, Alberta, Saskatchewan and Ontario. He is also the Board Chair of the Neighbourhood Pharmacy Association of Canada.

---

**ROSS GLOVER**

***General Manager, Taiho Pharma Canada Inc.***

Ross Glover is the General Manager of Taiho Pharma Canada, Inc. Ross is the leader of the Taiho Pharma Canada Executive Team and oversees the operations for the company in Canada, as well as the expansion into the Mexican pharma market. Ross has more than 30 years' experience in the pharma industry and his team is proud to have delivered two new options for oncology patients in Canada since opening the doors at Taiho in February 2017.

Prior to joining Taiho Pharma Canada, Ross was a member of the Canadian Leadership Team at Sanofi Genzyme and led the MS business unit. Prior to that, Ross held senior leadership positions in oncology and neurology and had built multi-functional teams to support the business and the clinical direction for breast cancer, colon cancer, lymphoma, epilepsy, Parkinson's disease, and multiple sclerosis. Ross has extensive experience in navigating the complicated Regulatory and Market Access process and has worked to develop some unique outcomes while making drugs available for patients who are in need.

---

**JAMES L. HALL**

***Senior Vice President and General Manager, Covis Pharma Canada***

Jim is currently the SVP and General Manager at Covis Pharma Canada. Prior to joining Covis, Jim held senior level commercial roles at several multinational pharmaceutical companies, and has more than 30 years of pharmaceutical industry experience in general management, sales, marketing, market access, operations and business development

In 2017, Jim was inducted into the Canadian Pharmaceutical Marketers Hall of Fame for his contributions to the industry and his support in the development of others.

For the past 8 years, Jim has been a seasonal lecturer in the MBA program at the DeGroote School of Business in Hamilton, Ontario.

Jim received his Bachelor of Engineering Science degree from the University of Western Ontario and Master of Business Administration from McMaster University.

---

**JOE KNOTT.**

***Co-chair, Managing Director, Pangaea Group***

As the founder of Pangaea, Joe brings 40 years of senior leadership as a strategic enabler to the healthcare industry. Driven by his deep understanding of the complex business challenges of today's healthcare organizations, Joe assembled Pangaea in 1995, a network of senior executives with the depth of expertise and knowledge to meet those challenges. Joe has extensive experience in the pharmaceutical industry, with 20 years in corporate positions and 20 developing and leading The Pangaea Group. He started his career with the Pennwalt Corporation and built upon this to ultimately become President of Fisons. He successfully launched numerous ethical and OTC products, negotiated strategic business alliances, and spearheaded Fisons into an era of strong growth driven by memorable sales and profit achievements. The success at Fisons shaped his vision to bring healthcare excellence to the broader industry which led to his transition to consulting and the creation of The Pangaea Group. Today, Joe remains ardently engaged in all areas of the practice. With a unique ability to integrate the most relevant market insights into strategy, Joe provides candid and thoughtful perspectives on the Canadian marketplace that bring meaningful and timely value to his clients and others. Joe passionately mentors stakeholders at all levels of industry to realize their potential. As an inductee to the Canadian Healthcare Marketing Hall of Fame, Joe's contributions to the industry run deep through numerous Board and Director positions including the Non-Prescription Drug Manufacturers' Association of Canada (now Consumer Health Products Canada [CHP]), Canadian Wholesale Drug Association (now Canadian Association for Pharmacy Distribution Management [CAPDM]), and the Pharmaceutical Manufacturers' Association of Canada (now Innovative Medicines Canada [IMC]). Joe is currently a cabinet member on the Canadian Blood Services committee for 'Campaign for All Canadians'.

---

**EILEEN MCMAHON**

***Partner, Torys LLP***

Eileen McMahon is a lawyer and partner with Torys LLP. She is the Chair of Torys' Intellectual Property and Food and Drug Regulatory Practices. Eileen is recognized nationally and internationally as a leading lawyer in the life sciences. Eileen and Torys are ranked #1 nationwide by Chambers in Life Sciences (the only lawyer/law firm to be so ranked). Eileen is a Certified Licensing Professional of the Licensing Executive Society (LES) (2011-2020), United States and Canada, having negotiated and concluded hundreds of commercial agreements in the life sciences industry. Eileen has been recognized in multiple national and international rankings, including: Best Lawyers'; Chambers & Partners' Chambers Global: *World's Leading Lawyers for Business*, Legal Lexpert Directory; *Who's Who Legal: Canada*; *Intellectual Asset Management's IAM Patent 1000: The World's Leading Patent Practitioners*; and *Who's Who Legal: International Who's Who of Life Sciences Lawyers*. Eileen is a member of the Board of Trustees of the Centre for Addiction and Mental Health (CAMH) and Chairs the Research Committee.

---

#### **RONNIE MILLER**

***President and CEO, Hoffmann-La Roche Limited***

Ronnie Miller is the President and CEO of Hoffmann-La Roche Limited (Roche Canada). In this role, he is responsible for the growth and success of the Canadian Pharmaceuticals Division, particularly as it relates to the company's mandate of developing and delivering innovative healthcare solutions for Canadians. Ronnie has more than 40 years of extensive and varied experience in the pharmaceutical industry. After completing his Bachelor of Science in Economics and Geography at the University of Glasgow, Ronnie moved to London to accept a job as a pharmaceutical sales representative. He advanced through a series of successive sales and management positions across the industry to become the National Sales Manager for Roche in the United Kingdom in 1979, and continued to move globally as a Product Manager in Switzerland and Deputy Divisional Director of the Pharmaceutical Division in Japan. Ronnie was appointed President and CEO of Roche Pharmaceuticals in Canada in April 2000. During his years in the pharmaceutical industry, Ronnie has seen the sector transition from a one-size-fits-all approach to one that is focused on the individual and the delivery of precision medicine. Ronnie believes that Roche, as an organization that has embraced this philosophy, is well positioned to maintain its leadership in innovating the way healthcare is delivered through the integration of its Pharmaceutical (Commercial and Product Development) and Diagnostics divisions. Ronnie was recently re-elected as the Chairman of the Board of Directors of Innovative Medicines Canada (IMC), the national association representing Canada's research-based pharmaceutical companies. He was previously Chairman of the IMC Board in 2007 and has since fulfilled two subsequent terms as Past Chair. Prior to this, Ronnie was the Chair of the IMC Prairies Core Team and sat as Co-Chair of the Health Research Foundation. He also served on several committees including the IMC Public Affairs, Stakeholder Relations, the British Columbia Sub-Committee, and was Chair of the Federal Affairs/FPT Relations Standing Committee. Ronnie is a member of the Swiss Canadian Chamber of Commerce.

---

#### **BEN PARRY**

***Co-Chair, Associate Managing Director, Pangaea Group***

Ben Parry is a Director based in Toronto who brings more than a decade of collaboration with executive teams in shaping and implementing strategy.

Ben enjoys supporting his clients' success through hands-on mentorship and advisory as well as helping new companies establish and launch efficiently in Canada. He has assisted numerous healthcare organizations with commercialization, channel optimization and trade integration of pharmaceuticals, medical devices, over-the-counter and natural health products.

Ben has managed a trade portfolio that included products from all major pharmaceutical manufacturers in Canada with deep experience in enterprise demand planning, integrated trade development, supply chain optimization and financial risk management. Ben is a rapidly deployable advisor with a unique ability to develop prompt meaningful results that unlock working capital and break down barriers in healthcare policy and operations.

Ben has also managed relationships with leading pharmacy retailers and contributed to numerous advisory boards and work groups in the areas of commercial optimization, big data, regulatory and market access.

---

## **PAUL PETRELLI**

### **General Manager, Jazz Pharmaceuticals Canada**

A business leader in the biotechnology/pharmaceutical industry, Paul Petrelli has a proven track record of performance and experience leading people and business in biotechnology and rare disease in both Canada and the United States. His experience includes building and growing businesses with companies like GlaxoSmithKline, AstraZeneca, Biogen and Jazz Pharmaceuticals. His 20 years of proven success is built on extensive launch experience; life cycle management; and breadth of understanding in sales, marketing, market access, medical, government relations and regulatory. Paul has also led organizations in creating a winning culture, with Biogen being recognized as a Great Place to Work in Canada for multiple years.

Paul is a member of the board of the Lymphoma and Leukemia Society of Canada; the Biomedical Discovery and Commercialization Program at McMaster University Department of Biochemistry and Biomedical Sciences; and BIOTECanada, where he serves as chair. Paul is also Director-in-Residence at the Rotman School of Management Director Education Program. He serves as faculty on the Marketing Pharmaceuticals in Canada Program and the National Pharmaceutical Congress.

Paul holds a Bachelor of Science degree, Genetics Specialist, from the University of Toronto and is a graduate of the Institute of Corporate Directors program at the Rotman School of Management, University of Toronto.

---

## **SYLVIE PILON**

### **Former Vice -President, General Manager, Lundbeck Canada**

With more than 30 years of experience in the pharmaceutical and biotechnology industry, Sylvie is a



passionate people leader driven by purpose with a track record of success. She is the former Vice President and General Manager of Lundbeck Canada where she brought the Canadian affiliate to new levels of performance by successfully implementing a clear corporate strategy while ensuring that employees were motivated and aligned under a common vision and purpose. Prior to this position, Sylvie was the head of Lundbeck Canada Mental Health Business Unit, where she helped achieve the company's goals through a period of intense change. She also created a new Oncology Business unit within the company, building a franchise from the ground up to launch two important chemotherapies for Leukemia and Lymphoma. Before joining Lundbeck, Sylvie worked in various roles with increasing responsibility at Novartis, Amgen and Berlex. Sylvie has her B.Sc. in Biochemistry Nutrition and her Executive Institute Advanced Management Certificate from McGill University and was also inducted into the Canadian Healthcare Marketing Hall of Fame.

---

### **MARISSA POOLE**

*Country Lead, Sanofi Canada and General Manager, Sanofi Genzyme Canada.*

With more than 25 years in the healthcare industry, Marissa has built her career in the pharma and biotech industry with deep expertise in clinical research and development, operations, commercialization and medical affairs. She has been pivotal in the development, approval and launch of transformative and lifesaving medicines in oncology, transplant, rare disease, immunology and neurology.

With leadership experience in Australia, US and Canada, Marissa is passionate about the value the life sciences industry brings to enable a healthier and safer future. She is a strong advocate to ensure that innovation and investment continues to be valued and recognizes the importance of true partnership across industry, academia, patient communities, public and private sectors to ensure better health outcomes for all Canadians. She co-leads the North America Gender Balance Leadership network and Inclusion & Diversity Council at Sanofi Canada.

Marissa has degrees in Pharmacology and Law from the University of Sydney.

---

### **DANIELLE PORTNIK**

*Product Manager, Mallinckrodt Pharmaceuticals & HBA Toronto President*

As the Canadian Product Manager with Mallinckrodt Pharmaceuticals, Danielle leads the national marketing strategy for in-market medications and has led substantial business development initiatives for Canadian drug and medical device commercialization. Her strong business-clinical background, passion and drive have curated innovative, high impact programs and healthcare partnerships. She has been recognized by both local and global colleagues for her unique strategies and outstanding brand growth, and by national organizations in respiratory and neonatal critical care for her contributions to excellence in the field.

Danielle is also a Co-Founder and President of the Board of Directors for the first Canadian Healthcare Businesswomen's Association (HBA) Chapter, established in 2019. She has led the board in becoming the fastest Affiliate to achieve Chapter status, doubling the organizational footprint while partnering with local and national organizations and healthcare executives to curate opportunities for the

advancement of women in the business of healthcare. Danielle is also a mentor and speaker at the Ryerson Science Discovery Zone incubator aimed at fostering entrepreneurial ventures. She holds a Certified Health Executive (CHE) designation with and has been published by the Canadian College of Health Leaders (CCHL), and holds Master of Biotechnology and Honours Bachelor of Science degree from the University of Toronto.

---

#### **ZAL PRESS**

##### ***Vice-Chair, CADTH Patient and Community Advisory Community***

Zal Press is Vice-Chair of the CADTH Patient and Community Advisory Committee which provides CADTH with advice on issues relevant to its mandate, from the perspective of those using the Canadian healthcare system. He founded Patient Commando, an organization dedicated to lifting the veil of silence that so often accompanies the onset of illness.

Zal has lived with Crohn's disease for 40 years. He is passionate about illustrating the need for improved health care policy and delivery by sharing stories that enrich our appreciation of the lived illness experience.

---

#### **DAVID RENWICK,**

##### ***Vice President & General Manager, Canada at Emergent***

David Renwick has more than two decades of experience driving the growth, value and efficiency of healthcare companies from start-up through all stages of growth. He has consistently led by example as a player coach who imparts the strategies, accountability, clarity, ownership and courage that empowers teams to exceed expectations, redefine the possible and compete where it counts. Applying a strong business acumen and challenging the status quo, David is passionate about addressing the unmet needs of individuals that are marginalized or stigmatized in our society. David led the launch of Narcan Nasal Spray in 2016 that has brought individuals and communities the ability to save thousands of lives due to the opioid crisis in Canada.

David was inducted into The Canadian Healthcare Marketing Hall of Fame in 2019 and holds a Bachelor of Arts in Economics from the University of Western Ontario.

David proudly sits on the Board Trustees for the Boys and Girls Clubs of Canada Foundation.

---

#### **MITCHELL SHANNON**

##### ***Co-chair, President, Chronicle Companies***

Mitch Shannon is the Publisher and co-founder (with Allan Ryan) of Chronicle Companies, which celebrates its 25th year in 2020. From locations in Toronto and Buffalo, N.Y., U.S.A., Chronicle produces

journals, periodicals, books, digital media and live events for medical specialists including Dermatologists, Plastic Surgeons, Neurologists, Psychiatrists, Pediatricians, and Family Doctors. Among the company's brands and imprints are: The Chronicle of Skin & Allergy, The Chronicle of Cosmetic Medicine + Surgery, Women in Dermatology, the annual Skin Spectrum Summit ethnodermatology conference series, the www.derm.city web portal, Linacre's Books, and the new Canadian Journal of Medical Cannabis. The company's business-to-business unit created and organizes the annual Canadian National Pharmaceutical Congress, now in its 13th iteration. Chronicle recently launched the "NPC Healthbiz Weekly" e-newsletter and the weekly "NPC Podcast," and will introduce the "Chronicle.Academy" e-learning portal to offer skills maintenance for life sciences managers and executives. Mitch is a graduate of the University of Toronto in Education and Arts, and studied graduate Journalism at the University of Oregon. He began his career as a medical writer in New York City and Toronto with the acclaimed MD Magazine, founded and edited by Dr. Felix Marti-Ibanez (and semi-secretly owned by the Sackler brothers.) He is the author of "Healthcare Babylon," a collection of essays on the pharmaceutical industry's efforts to adjust to the new millennium.

---

#### **CAROL STIFF**

***Carol Stiff, Head of Canada, Santen Canada Inc.***

Carol Stiff is Head of Canada for Santen Canada Inc. In her 4 years at Santen, Carol built and executed the Canadian entry plans for prescription, surgical device and OTC products in ophthalmology. Carol also played an extended role in supporting Santen USA in developing its patient services program.

Carol has spent the last 22 years in various roles in pharmaceutical and biotechnology in agency services, patient services, sales, marketing and organizational building. Her experience spans pain management, neurology, hematology, immunology and ophthalmology. Carol is graduate of the inaugural 2018-2019 cohort of the Centre for Drug Research and Development's (CDRD) Executive Institute.

---

#### **ARIMA VENTIN**

***Executive Director, Market Access, Pricing and Government Relations, Allergan (an AbbVie Company)***

Arima Ventin is strongly committed to the vision that healthcare companies should invest in therapies that fulfill unmet medical needs; engage the community in a positive way; and fill gaps in care in neglected therapeutic areas with a high impact on society. Arima is the Executive Director, Market Access, Pricing & Government Relations for Allergan Inc., an AbbVie Company, and has been in this role since August 2014. Prior to joining Allergan Arima was Director of Marketing and Market Access at Forest Laboratories, and Vice President of Marketing and Market Access at Basilea Pharmaceuticals Corp. Over the past 15 years she has held positions in sales, sales management, marketing, market research, analytics and strategic planning at Wyeth Pharmaceuticals and at Eli Lilly Canada. Arima is a member of the board of the Eczema Society of Canada and the IESE Alumni Association. Arima holds a B.Sc. in Pharmacy from the University of Toronto. Later, she earned her Master of Business Administration from the IESE School of Business at the University of Navarra in Barcelona, Spain. She is also a graduate of the IVEY Leadership Program at the Richard Ivey School of Business.

---

**TONY VOLPE**

***Senior Director, Business Development, Shoppers Drug Mart Specialty Health Network***

Tony Volpe has over 25 years of specialty pharmaceutical experience with demonstrated success in commercial growth, business development, portfolio and life cycle optimization, and building and managing high-performance teams. He has successfully led the launches of numerous specialty products and is passionate about advancing patient care.

Tony is currently the Senior Director, Business Development at Shoppers Drug Mart's Specialty Health Network—a leading provider of specialty drug distribution, pharmacy and comprehensive patient support services. Tony holds an MBA from Dalhousie University and a Bachelor of Arts from York University.